Skip to main content

Table 2 Multinomial logistic regression analyses

From: Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study

  visceral fat obesity premetabolic syndrome metabolic syndrome
Variable AOR 95% CI AOR 95% CI AOR 95% CI
Gender (male) 7.104 2.990-16.879 6.122 2.955-12.683 3.427 1.835-6.401
Smoking habit, per day       
   21 or more 0.353 0.093-1.337 1.726 0.750-3.974 2.298 1.074-4.916
   6 to 20 0.882 0.357-2.183 1.103 0.483-2.521 1.537 0.714-3.308
   1 to 5 0.480 0.054-4.286 0.784 0.144-4.266 0.736 0.143-3.799
   none (reference) 1 -- 1 -- 1 --
Duration of psychiatric treatment, y 1.006 0.974-1.039 0.990 0.962-1.019 1.028 1.003-1.054
Total daily dose (10 mg units) 1.011 1.003-1.019 1.007 0.999-1.015 1.005 0.998-1.012
Antipsychotic polypharmacy 1.580 0.709-3.521 2.348 1.181-4.668 1.269 0.679-2.371
  1. The dependent variable has four categories: normal, visceral fat obesity, pre-metabolic, and metabolic syndrome. The latter three categories are compared with the normal category.
  2. AOR: adjusted odds ratio, CI: confidence interval
  3. Nagelkere's R square = 0.26.